Enabling tomorrow’s biotherapeutics
Changing Cells With Light
Prolific Machines Appoints Christelle Dagoneau as Interim Chief Business Officer to Accelerate Commercial Growth and Strategic Partnerships
Light-controlled biomanufacturing for unmatched productivity and quality control
Prolific Machines’ next-generation cell line development and bioprocessing solutions offer dynamic, tunable control over protein expression with light - delivering breakthrough yields, superior on-target quality, and process control for even the most complex biologics.
The platform integrates with standard, available manufacturing infrastructure using add-on illumination hardware, data-driven process optimization, and advanced analytics.
We work with biotechs, pharmaceutical companies and CDMOs and provide preclinical cell line and process development services, as well as platform licensing options.
mAbs
Boost titers and CQA control for standard and complex monoclonal antibodies.
Bispecifics & multispecifics
Balance chain expression ratios for precise multispecific stoichiometry and higher titers.
Fc fusions
Control expression timing to optimise productivity and avoid common quality issues such as aggregation.
Cytokines
Tune expression levels to manage toxicity and improve yields for notoriously difficult molecules.
Enzymes & other proteins
Programme expression strategies for complex recombinant proteins beyond antibody formats.
AAV
Coming soonTime and control expression of multiple toxic components in stable HEK producer cell lines for viral vector manufacturing.
Industry-record titer · 15-day fed-batch
The highest reported productivity for a 15 day fed-batch mAb production run — achieved with standard infrastructure.
Partner with usEnables complex therapeutics
Enables complex therapeutics
Provides unprecedented CQA control
Precise, light-driven control over critical quality attributes.
Drop-in compatible
Works with your existing CLD platforms, processes and bioreactors.
Prolific's light-controllable cell lines unlock the manufacturability of complex biologics and provides low COGS manufacturing supply within fed-batch processes, using existing bioreactor capacity.
Optogenetics: Unprecedented control with light
Prolific harnesses light-responsive proteins to control gene expression inside living cells. Light acts as a precise dial, switching genes on and off to dynamically regulate the timing and level of protein production throughout the culture process.
This unlocks the ability to fully separate cell growth from production, eliminate the trade-offs between proliferation and productivity, and achieve precise control over post-translational modifications, capabilities that conventional bioprocessing has never been able to offer.
One powerful platform, three ways to partner
Prolific Machines enables delivery of complex biologics across the value chain, working with biopharma innovators, biosimilar developers, and CDMOs from pre-clinical CLD through commercial manufacturing. We deliver breakthrough yields, accelerated timelines, and quality Drug Substance supply —without disrupting the infrastructure and platforms you already rely on.
1. Integrated Bio Development Solutions
Cell Line & Process Development, Non-GMP Manufacturing and Analytical Chemistry - tech transferred to CDMO partners.
A superior approach to complex biologics development that enables and accelerates path to clinic.
2. Platform Licensing for In-House Enablement
A complete solution to build your in-house optogenetic manufacturing capability
Leverage your platform IP, existing capacity and manufacturing know-how, while gaining step-change performance
3. CDMO Partnerships for GMP Supply
Comprehensive CDMO partnerships for scaled up GMP supply with smooth tech transfers and complete technology and services support
Explore In-House Solutions
A step-change in complex biologics manufacturing
Prolific's Platform delivers what conventional bioprocessing cannot: dynamic, programmable control over cellular behaviour at the molecular level — addressing the industry's most persistent manufacturing challenges.
Prolific supports biopharma innovators, biosimilar developers and CDMOs with a full suite of integrated or tailored solutions to deliver the next biologic. We will:
Deliver production cell lines or enable your host cell line
Deliver pre-clinical biologic drug substance
Deliver IND package (part of FDA’s Emerging Technology Program)
Support tech transfer to pharma or CDMO
Provide full analytical support
Facilitate a tech transfer to a partnered CDMO or your in-house facility for GMP supply with full equipment, scientific, analytical and optimization support
About Us
At Prolific, biologists, engineers, and data scientists collaborate as one to connect biological regulation with modern bioprocess control.
Founded in 2020, Prolific Machines pioneered the use of optogenetics to bring dynamic, light-based control to biomanufacturing. We are the first to integrate optogenetic cell line development, plug-and-play illumination, and data-driven process optimization into industrialized solutions for therapeutics production.
Maximilian Hörner, PhD - Head of Optogenetics
Shahram Misaghi, PhD - Research Fellow, Head of CLD
Amritha Menon, MS - Senior Scientist
Kiana Mohajeri, PhD - Head of Synthetic Biology
Latest new and Perspectives
Prolific Machines Appoints Christelle Dagoneau as Interim Chief Business Officer to Accelerate Commercial Growth and Strategic Partnerships
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
Prolific Machines Selected to Join FDA's Emerging Technology Program, Advancing the Company’s Novel Biomanufacturing Platform
Events
BIO International
BioProcessing Summit
BioProcess International
CPhI
Festival of Biologics
PEGS Europe